Form 4: Alzamend Neuro Director Milton C. Ault III Reports Stock Purchase
SEC Form 4 Filing
Director Milton C. Ault III reports purchasing 100 shares of Alzamend Neuro, Inc. common stock at $0.6842 per share.
Summary
- On March 12, 2025, Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc., purchased 100 shares of common stock at a price of $0.6842 per share.
- The purchase was made in open market transactions.
- Following the transaction, Ault directly owns 16,686 shares.
- Ault also indirectly owns 77,368 shares through Ault Lending, LLC, 99,619 shares through Ault Life Sciences, Inc., and 549 shares through Ault Life Sciences Fund, LLC.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports a transaction. It doesn't indicate positive or negative outlook.
Positives
- The director's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of regulatory compliance for corporate insiders and large shareholders, providing transparency into their trading activities.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/12/2025 | Date of stock purchase transaction. |
| 03/14/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.